NSCLC Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 10+ Companies and 10+ Therapies
DelveInsight's, 'Non-Small-Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the NSCLC Treatment Landscape. Click here to read more @ NSCLC Pipeline Outlook
Key Takeaways from the NSCLC Pipeline Report
In June 2025, Revolution Medicines Inc. announced a study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel. This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve progression free survival (PFS) or overall survival (OS) compared to docetaxel chemotherapy in patients with NSCLC who were previously treated. Patients will be randomized in a 1:1 ratio to receive daraxonrasib or docetaxel chemotherapy.
In June 2025, Amgen conducted a study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR).
In June 2025, Allist Pharmaceuticals Inc. organized a Phase 3 clinical study to assess the efficacy and safety of adjuvant treatment with firmonertinib versus placebo in participants with Stage IB-IIIB NSCLC with uncommon EGFR mutations (exon 20 insertions, PACC and classical-like mutations) after complete surgical resection with or without adjuvant chemotherapy.
In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.
DelveInsight's NSCLC pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for NSCLC treatment.
The leading NSCLC Companies such as GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others.
Promising NSCLC Pipeline Therapies such as Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others.
Stay informed about the cutting-edge advancements in NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ NSCLC Clinical Trials Assessment
NSCLC Emerging Drugs Profile
AMG 510: Amgen
AMG 510 is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocancer patients and 5% of colorectal cancer patients, and AMG 510 is the first drug candidate to target this mutation, there have been high expectations for the drug. The Food and Drug Administration has granted a fast track designation to AMG 510 for the treatment of metastatic non-small-cell lung cancer with the G12C KRAS mutation. The drug is in preregistration stage for the treatment of NSCLC.
CMP 001: Cytos Biotechnology
CMP 001 is a short piece of DNA, called an oligonucleotide that Checkmate designed to mimic the DNA of bacteria. It encapsulated the DNA in noninfectious virus-like particles, or VLPs. The company created CMP-001 to be administered directly to a tumor. When this occurs, the immune system sees VLPs as foreign. It generates immune cells called antigen presenting cells that release the DNA from the VLPs. CMP 001 is in phase 1 of clinical trials for the treatment of non-small cell lung cancer.
The NSCLC Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of NSCLC with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NSCLC Treatment.
NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different NSCLC mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NSCLC market
Learn more about NSCLC Drugs opportunities in our groundbreaking NSCLC research and development projects @ NSCLC Unmet Needs
NSCLC Companies
GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others.
Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Subcutaneous
Intravenous
Oral
Parenteral
Intramuscular
Molecule Type
NSCLC Products have been categorized under various Molecule types such as
Small molecules
Peptides
Polymer
Gene Therapy
Monoclonal antibodies
Product Type
Discover the latest advancements in NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ NSCLC Market Drivers and Barriers, and Future Perspectives
Scope of the NSCLC Pipeline Report
Coverage- Global
NSCLC Companies- GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others.
NSCLC Pipeline Therapies- Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others.
NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of NSCLC Pipeline on our website @ NSCLC Emerging Drugs and Companies
Table of Contents
Introduction
Executive Summary
Non-Small-Cell Lung cancer (NSCLC): Overview
Pipeline Therapeutics
Therapeutic Assessment
Non-Small-Cell Lung cancer (NSCLC) – DelveInsight's Analytical Perspective
In-depth Commercial Assessment
Late Stage Products (Pre Registration)
AMG 510: Amgen
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug Name: Company Name
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
CMP 001: Cytos Biotechnology
Inactive Products
Non-Small-Cell Lung cancer (NSCLC) Key Companies
Non-Small-Cell Lung cancer (NSCLC) Key Products
Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs
Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers
Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion
Non-Small-Cell Lung cancer (NSCLC) Analyst Views
Non-Small-Cell Lung cancer (NSCLC) Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Vogue Arabia
an hour ago
- Vogue Arabia
Why Seed Cycling is Taking Over Women's Wellness Routines
For decades, conversations around hormonal health have largely remained in the realm of clinical consultations and pharmaceutical fixes. Like many women, we've all faced our share of hormonal ups and downs—cramps and cravings, PMS mood swings, or that strange in-between phase when our body seems to turn against us with breakouts or unexplained irritation. Now, there's a quiet but powerful shift happening in women's wellness, but in kitchens. And one of the most unexpected entries into this conversation? Seeds. Yes, women are rotating ground flax, pumpkin, sesame, and sunflower seeds based on the phases of their menstrual cycles. It's called seed cycling, a naturopathic-inspired practice gaining popularity for its promise to gently support hormonal balance. 'The nutrients in these seeds may influence hormone levels and alleviate symptoms related to hormonal imbalances. Some studies suggest that seed cycling may help regulate hormones and support menstrual cycle regularity, particularly in conditions like polycystic ovary syndrome (PCOS). Some have also shown a reduction in the number of cysts when combined with calorie control and exercise,' reasons Zeina Soueidan, a registered/licensed nutritionist and health coach. At its core, seed cycling is a functional food-based practice where women consume specific types of seeds during the two primary phases of their menstrual cycle. 'During the follicular phase (days 1–14), flax and pumpkin seeds are consumed to support estrogen production. In the luteal phase (days 15–28), sesame and sunflower seeds are consumed to support progesterone levels,' says Zeina. There's a reason why these specific seeds are chosen because of their nutrient-dense properties, that is believed to support the natural ebb and flow of estrogen and progesterone. Here's how: Flaxseeds are rich in lignans (phytoestrogens), fiber, and omega-3s, which may modulate estrogen levels and reduce inflammation. Pumpkin seeds offer zinc and lignans like secoisolariciresinol, supporting progesterone production. Sesame seeds, high in lignans and omega-6s, help maintain progesterone during the luteal phase. Sunflower seeds provide vitamin E and selenium, vital for hormone synthesis and healthy follicle function. And they're simple to add to your everyday food, from breakfast to dinner. Ground flax and pumpkin seeds blend smoothly into smoothies. Toasted sesame and sunflower seeds bring a satisfying crunch to salads, grain bowls, and acai bowls. They also work well in homemade granola, energy bars, or simply sprinkled over yogurt for a quick nutrient boost.
Vogue Arabia
2 days ago
- Vogue Arabia
10 Foods That Naturally Lower Cortisol Levels
If you spend a lot of time on TikTok, then you'll be familiar with the phrase 'cortisol face'. Characterised by puffiness and swelling of the face and neck, cortisol face has become a much bandied-about term. Cortisol – known as the 'stress hormone' – is produced by the adrenal glands as a response to stressful or dangerous situations. Essential for our survival, it regulates immune response, blood sugar and blood pressure. In excess, though, it can affect our lymphatic system and cause puffiness in the eyes, cheeks and jaw. While scientific research into the concept of cortisol face is lacking, anecdotal evidence abounds. However, experts are keen to stress that signs of 'cortisol face' could actually be related to taking steroids, or to Cushing's syndrome – a (very) rare condition that occurs when the body produces too much cortisol. Too much cortisol for too long is not good for anyone's health. In ideal circumstances, the body naturally lowers cortisol levels when the stress or 'threat' has passed, but if stress persists for a long time, high cortisol levels can keep the body in a 'fight or flight' state. This can inhibit the immune system and alter the gut microbiome, making us vulnerable to inflammation and infection, as well as potentially causing fatigue, irritability, headaches, brain fog, acne, insomnia, weight gain and even anxiety and depression. Mitigating all of the stress in our lives is largely impossible. However, there are ways to manage it – be that through mindfulness, meditation, pranayama, yoga, moderate exercise or just regular, good-quality sleep. Similarly, a healthy, balanced diet that's low in refined sugars, saturated fats, excess alcohol and caffeine – all things that can raise cortisol – but rich in adequate omega-3, magnesium, fibre and antioxidants, can help counteract cortisol. Here are the best foods to include in your diet if tackling stress is your main concern. 1. Leafy greens Leafy green vegetables such as spinach, arugula and kale are chock-full of vitamins, minerals and antioxidants. They are also rich in folate, which can help to regulate cortisol levels and promote a healthy gut microbiome, essential for the production of neurotransmitters such as serotonin, another cortisol mitigator. 2. Bitter chocolate It's not news that small amounts of dark chocolate – containing at least 70% cocoa – is good for you. Rich in antioxidants, it's healthier than milk or white alternatives. Less well known is the fact that the flavonoids in cocoa can help mitigate the stress response from the adrenal glands and the subsequent release of cortisol. Plus, chocolate can help put you in a better mood. 3. Green tea Rich in catechins, a category of antioxidant polyphenols, and L-theanine, an amino acid that promotes relaxation, green tea is soothing and energising at the same time, and the ideal drink to sip when you're stressed out. Consume it in loose leaf, tea bag or matcha form. It can also be added to smoothies and desserts. 4. Salmon Perhaps the ultimate skin-friendly food, salmon (like other types of fish rich in healthy fats, like sardines and mackerel), can help regulate cortisol levels, thanks to its anti-inflammatory omega-3 content. In fact, some studies have found that fish oils can counteract adrenal gland activation in stressful situations. 5. Avocado Another skin-loving food, avocado contains significant amounts of potassium, as well as magnesium, an anti-stress mineral that promotes sleep and muscle relaxation by helping to counteract cortisol. Pair it with a boiled or poached egg on toast for a balanced breakfast. 6. Legumes Chickpeas, beans and fava beans, as well as lentils, peas and lupins, are all excellent sources of fibre that support gut health and regulate blood sugar. In addition, they are rich in B vitamins and magnesium, both of which contribute to the healthy function of the nervous system. 7. Berries Blackberries, blueberries, cranberries, raspberries and the like are tiny powerhouses of free radical-fighting antioxidants. Because of this, they reduce oxidative stress and cortisol levels. Add berries to smoothies and yoghurt, or eat them with a handful of almonds and walnuts. 8. Nuts Almonds, walnuts, hazelnuts, cashews, and Brazil nuts all have anti-stress properties, thanks to their combination of good fats, magnesium, B vitamins, and antioxidants. Add them to salads and pasta dishes, or keep a stash handy to snack on between meals. 9. Eggs In addition to being an outstanding source of quality protein, vitamins and minerals, eggs contain choline, an essential nutrient that plays a vital role in brain health, and helps to reduce stress and anxiety by improving emotional wellbeing. Eating a protein-rich, egg-based breakfast in the morning can be an easy way to stay full and satisfied until lunch. 10. Chia seeds Rich in anti-inflammatory omega-3s, chia seeds help to lower cortisol levels and promote a sense of calm. Make chia seed pudding with dairy or non-dairy milk, add them to smoothies, or create an easy chocolate mousse by soaking them in almond milk and then blending them with pure cocoa, with a teaspoon of maple syrup or honey for added sweetness. Article originally published on Vogue Italy
Globe and Mail
2 days ago
- Globe and Mail
NSCLC Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 10+ Companies and 10+ Therapies
DelveInsight's, 'Non-Small-Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the NSCLC Treatment Landscape. Click here to read more @ NSCLC Pipeline Outlook Key Takeaways from the NSCLC Pipeline Report In June 2025, Revolution Medicines Inc. announced a study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel. This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve progression free survival (PFS) or overall survival (OS) compared to docetaxel chemotherapy in patients with NSCLC who were previously treated. Patients will be randomized in a 1:1 ratio to receive daraxonrasib or docetaxel chemotherapy. In June 2025, Amgen conducted a study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR). In June 2025, Allist Pharmaceuticals Inc. organized a Phase 3 clinical study to assess the efficacy and safety of adjuvant treatment with firmonertinib versus placebo in participants with Stage IB-IIIB NSCLC with uncommon EGFR mutations (exon 20 insertions, PACC and classical-like mutations) after complete surgical resection with or without adjuvant chemotherapy. In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC. DelveInsight's NSCLC pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for NSCLC treatment. The leading NSCLC Companies such as GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. Promising NSCLC Pipeline Therapies such as Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others. Stay informed about the cutting-edge advancements in NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ NSCLC Clinical Trials Assessment NSCLC Emerging Drugs Profile AMG 510: Amgen AMG 510 is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocancer patients and 5% of colorectal cancer patients, and AMG 510 is the first drug candidate to target this mutation, there have been high expectations for the drug. The Food and Drug Administration has granted a fast track designation to AMG 510 for the treatment of metastatic non-small-cell lung cancer with the G12C KRAS mutation. The drug is in preregistration stage for the treatment of NSCLC. CMP 001: Cytos Biotechnology CMP 001 is a short piece of DNA, called an oligonucleotide that Checkmate designed to mimic the DNA of bacteria. It encapsulated the DNA in noninfectious virus-like particles, or VLPs. The company created CMP-001 to be administered directly to a tumor. When this occurs, the immune system sees VLPs as foreign. It generates immune cells called antigen presenting cells that release the DNA from the VLPs. CMP 001 is in phase 1 of clinical trials for the treatment of non-small cell lung cancer. The NSCLC Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of NSCLC with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NSCLC Treatment. NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different NSCLC mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NSCLC market Learn more about NSCLC Drugs opportunities in our groundbreaking NSCLC research and development projects @ NSCLC Unmet Needs NSCLC Companies GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Subcutaneous Intravenous Oral Parenteral Intramuscular Molecule Type NSCLC Products have been categorized under various Molecule types such as Small molecules Peptides Polymer Gene Therapy Monoclonal antibodies Product Type Discover the latest advancements in NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ NSCLC Market Drivers and Barriers, and Future Perspectives Scope of the NSCLC Pipeline Report Coverage- Global NSCLC Companies- GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. NSCLC Pipeline Therapies- Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others. NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of NSCLC Pipeline on our website @ NSCLC Emerging Drugs and Companies Table of Contents Introduction Executive Summary Non-Small-Cell Lung cancer (NSCLC): Overview Pipeline Therapeutics Therapeutic Assessment Non-Small-Cell Lung cancer (NSCLC) – DelveInsight's Analytical Perspective In-depth Commercial Assessment Late Stage Products (Pre Registration) AMG 510: Amgen Drug profiles in the detailed report….. Mid Stage Products (Phase II) Drug Name: Company Name Drug profiles in the detailed report….. Early Stage Products (Phase I) CMP 001: Cytos Biotechnology Inactive Products Non-Small-Cell Lung cancer (NSCLC) Key Companies Non-Small-Cell Lung cancer (NSCLC) Key Products Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion Non-Small-Cell Lung cancer (NSCLC) Analyst Views Non-Small-Cell Lung cancer (NSCLC) Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
